Clinical Trial Update: An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial of ALD403 (eptinezumab) in chronic migraine completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• ALD403

Snippet

Sponsor: Alder Biopharmaceuticals, Inc. | Conditions: Migraine Disorder | Phase 3 | Status: COMPLETED | Results posted: 2020-04-21